In male mice, THC-driven hyperlocomotion depends on CB1 signaling

Psychotomimetic Cannabinoid Hyperlocomotion Involves GSK-3β Signaling at Striatopallidal Neurons in Male Mice.

Biological psychiatry global open science • • Highly Relevant
🤖

AI Summary

This abstract-based summary covers a laboratory study asking how THC causes psychotomimetic-like hyperlocomotion. Researchers used pharmacological and genetic manipulations in cultured cells and adult male mice, testing a low dose of THC (0.3 mg/kg) and measuring locomotor activity. The reported behavioral effect depended on CB1 receptors on dopamine D2 receptor-positive striatopallidal neurons and on signaling involving β-arrestin 1, Akt, and GSK-3β.

The study also reports that pregnenolone and its clinically developed analog AEF0117, described as signaling-specific CB1 receptor inhibitors, prevented THC-induced, GSK-3β-dependent psychomotor stimulation in mice. The findings identify a possible cellular mechanism and research lead, but they do not establish a treatment for psychosis or show that the same mechanism or effects occur in people. The work was conducted in male mice and cultured cells; this abstract-based summary cannot assess details beyond what the abstract reports.

💡 Key Findings

1
In male mice, hyperlocomotion after low-dose THC (0.3 mg/kg) depended on CB1 receptors on dopamine D2 receptor-positive striatopallidal neurons.
Good
75%
2
The reported hyperlocomotor effect required β-arrestin 1/Akt/GSK-3β signaling, according to pharmacological and genetic manipulations.
Good
70%
3
Pregnenolone and AEF0117 prevented THC-induced, GSK-3β-dependent psychomotor stimulation in the mouse experiments; the abstract does not establish clinical efficacy in people.
Good
70%

📄 Original Abstract

BACKGROUND: Hyperlocomotion induced by psychotomimetic agents is considered a proxy for positive psychotic-like symptoms and is used in antipsychotic drug screenings with rodents. Cannabinoids are psychotomimetic drugs in humans, and low doses of cannabinoid CB1 receptor (CB1R) agonists induce hyperlocomotion in rodents. However, the cellular and molecular mechanisms underlying this effect remain unexplored so far. METHODS: We used a combination of pharmacological and genetic manipulations in cultured cells and adult male mouse models, together with an intracellular signaling detection method. Our multidisciplinary approach included locomotor activity (n = 10-12 mice/group), alphaLISA technology (n = 4-12 mice/group), transfection of the β-arrestin 1 protein in STHdh Q7/Q7 cells (n = 4-6/group) and a viral strategy in transgenic lines to selectively block GSK-3β (glycogen synthase kinase-3β) phosphorylation (n = 8-10 mice/group). We also used fluorescence in situ hybridization, real-time quantitative and droplet digital polymerase chain reaction, and tandem mass spectrometry. RESULTS: We showed that the hyperlocomotion induced by a low dose (0.3 mg/kg) of cannabinoid Δ9-tetrahydrocannabinol depends on the activation of plasma membrane CB1R located on dopamine D2 receptor-positive striatopallidal projecting neurons. This activation regulates the β-arrestin 1/Akt/GSK-3β signaling pathway, which is required for the hyperlocomotor effect. The signaling-specific CB1R inhibitors, pregnenolone and its clinically developed analog, AEF0117, prevent GSK-3β-dependent psychomotor stimulation induced by THC. CONCLUSIONS: This work highlights an intracellular mechanism of CB1R expressed by a selective key neuronal pathway mediating the psychotomimetic effect of THC and, by extension, low-dose cannabis consumption. This discovery will likely aid the development of unprecedented therapeutic modalities for the treatment of psychotic conditions. Studies have shown a link between acute psychotic-like symptoms and exposure to cannabis or its main psychoactive component, Δ9-tetrahydrocannabinol (THC), in both humans and animal models. Here, we demonstrate the cellular and molecular mechanisms underlying THC-induced psychotomimetic hyperlocomotion in male mice. These mechanisms involve cannabinoid CB1 receptor (CB1R)–mediated, β-arrestin 1–dependent inhibition of GSK-3β signaling activity in the cerebello–basal ganglia pathway. Additionally, we demonstrate that the signaling-specific CB1R inhibitors, pregnenolone and its clinically developed analog AEF0117, prevent GSK-3β–dependent psychomotor stimulation induced by THC. These findings shed light on new therapeutic approaches for psychotic disorders associated with cannabinoids.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.